5-Azacytidine injections for muscle contractures in children with cerebral palsy
Tests 5-azacytidine injections for safety in children with cerebral palsy and muscle contractures.
Key facts
- Who runs it
- Shirley Ryan AbilityLab
- Where
- San Diego, United StatesSee the site
- Trial code
- Registry title
- Repurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral Palsy
- Status
- Enrolling by invitation
- Phase
- Phase 1
- People taking part
- 27 people, planned
- Started
- Jul 2025
- Expected to end
- Jul 2027
- Type of study
- Interventional, 8 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Placebo for the AZA 10mg/m^2
- Placebo for the AZA 20mg/m^2
- Placebo for the AZA 35mg/m^2
- Placebo for the AZA 75mg/m^2
- 5-Azacytidine 10mg/m^2
- 5-Azacytidine 20mg/m^2
- 5-Azacytidine 35mg/m^2
- 5-Azacytidine 75mg/m^2
- Record updated
- 3 July 2025
Who can take part
The trial is looking for children and teens with cerebral palsy who need surgery to lengthen a tight Achilles or hamstring muscle. It tests one injection of 5-azacytidine (AZA) against a placebo, a look-alike shot with no drug.
- Age
- 2 to 18 years
- Sex
- All sexes
- Disease stage
- Cerebral palsy with stiff (spastic) Achilles or hamstring muscles and a fixed tightening (contracture) that needs surgical lengthening.
- Earlier treatment
- No chemotherapy in the past three months.
- Biomarker or test result
- Normal kidney and liver blood tests: creatinine ≤ 1.0 times the upper limit of normal, AST or ALT ≤ upper limit of normal, total bilirubin ≤ 1.0 times the upper limit of normal. Girls who can become pregnant need a negative pregnancy test.
- Main reasons for not taking part
- Active infection
- Heart disease
- Allergy to AZA or mannitol
- Blood disorder or other cancer
- Chemotherapy in the past three months
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Diagnosis of cerebral palsy
- Either achilles or hamstring spasticity with contracture necessitation surgical lengthening
- Between 2 and 18 years of age
- Normal renal and liver function as defined by NCI-CTCAE criteria.71; Renal Function (Grade 0 - Normal): i. Creatinine: Within the normal range or ≤ 1.0 times the upper limit of normal (ULN); Glomerular filtration rate (GFR): No significant decrease. b. Liver Function (Grade 0 - Normal): i. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT): Within the normal range or ≤ ULN; Total bilirubin: Within the normal range or ≤ 1.0 times ULN
- A negative pregnancy test for females of childbearing potential*
- Females of childbearing potential must agree to use contraception consistently from screening to 6 months after their injection. Highly effective methods of contraception are required for females of childbearing potential:; Total abstinence from sexual intercourse; Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS); Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, which may be oral, intravaginal, or transdermal used in accordance with medical direction; Progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injected, or implanted, and used in accordance with medical direction
- Males of childbearing potential** must agree to use contraception consistently from screening until 3 months after the injection. Acceptable methods of contraception for males of childbearing potential are:; Total abstinence from sexual intercourse; Condom with spermicide (cream, spray, foam, gel, suppository, or polymer film); Female of childbearing potential is defined as a female capable of becoming pregnant, which includes patients who have had their first menstrual cycle (menarche); Male of childbearing potential is defined as a subject who has reached spermarche
Who cannot take part
- Received chemotherapy in the preceding three months
- Active infection
- Cardiac disease
- Allergy to AZA or mannitol
- Evidence of a hematologic precondition or other malignancy
- Patient or family who is non-compliant
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Cerebral palsy or contracture
Where in United States
- Rady Children's Hospital - San DiegoSan Diego, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
In this controlled dose-escalation study, we will study the initial safety, biological properties, and potential efficacy of 5-azacytidine (AZA). Our overarching aspiration is for AZA to evolve into an approved pharmacological treatment, fostering muscle growth and enhancing body movement, ultimately contributing to an improved quality of life in children with CP.
Read full original descriptionShow less
The main questions this study aims to answer are:
1. What is the optimal dose of AZA injection that can be used safely in children with CP? 2. Can the optimal safe dose of AZA improve the function of muscle-generating stem cells in children with CP?
Each participant will have up to five research visits over the course of the study duration, in which they will participate in: blood draws, pregnancy test(s) (if applicable), medical assessments, and a muscle biopsy during a surgery for muscle contractures.
Researchers will compare participants with four different dosages of AZA injections to those with four different dosages of placebo injections. A placebo is a look-alike substance that contains no active drug. They will see if a single injection of AZA at a standard concentration currently approved by the FDA to treat myelodysplastic syndromes, can also safely improve muscle growth and function in children with CP.
The 8 groups in the trial
- AZA 10mg/m^2Treatment being tested
5-Azacytidine, subcutaneous injection, 10mg/m\^2, one subcutaneous injection for duration of study (estimated at 46 - 76 days)
Treatment: 5-Azacytidine 10mg/m^2
- AZA 20mg/m^2Treatment being tested
5-Azacytidine, subcutaneous injection, 20mg/m\^2, one subcutaneous injection for duration of study (estimated at 46 - 76 days)
Treatment: 5-Azacytidine 20mg/m^2
- AZA 35mg/m^2Treatment being tested
5-Azacytidine, subcutaneous injection, 35mg/m\^2, one subcutaneous injection for duration of study (estimated at 46 - 76 days)
Treatment: 5-Azacytidine 35mg/m^2
- AZA 75mg/m^2Treatment being tested
5-Azacytidine, subcutaneous injection, 75mg/m\^2, one subcutaneous injection for duration of study (estimated at 46 - 76 days)
Treatment: 5-Azacytidine 75mg/m^2
- Placebo for 10mg/m^2Placebo, for comparison
Placebo, subcutaneous injection, 10mg/m\^2, one subcutaneous injection without the active treatment for duration of study (estimated at 46 - 76 days)
Treatment: Placebo for the AZA 10mg/m^2
- Placebo for 20mg/m^2Placebo, for comparison
Placebo, subcutaneous injection, 20mg/m\^2, one subcutaneous injection without the active treatment for duration of study (estimated at 46 - 76 days)
Treatment: Placebo for the AZA 20mg/m^2
- Placebo for 35mg/m^2Placebo, for comparison
Placebo, subcutaneous injection, 35mg/m\^2, one subcutaneous injection without the active treatment for duration of study (estimated at 46 - 76 days)
Treatment: Placebo for the AZA 35mg/m^2
- Placebo for 75mg/m^2Placebo, for comparison
Placebo, subcutaneous injection, 75mg/m\^2, one subcutaneous injection without the active treatment for duration of study (estimated at 46 - 76 days)
Treatment: Placebo for the AZA 75mg/m^2
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Repurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral Palsy
- Plain-language title
- 5-Azacytidine injections for muscle contractures in children with cerebral palsyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT06377085, who can take part
- Record updated
- 3 July 2025